StockDuty ← Dashboard Sep 18, 2026 01:51 PM ET
CatalystFDA/Bio

Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

Arcturus presents Phase 2 OTC deficiency data plus mRNA liver platform update.

What changed
Arcturus presents Phase 2 OTC deficiency data plus mRNA liver platform update.
Why it matters
Arcturus presents Phase 2 OTC deficiency data plus mRNA liver platform update. — impact context not separately stored; see What changed.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →